Discriminative Stimulus Effects of the Cannabinoid CB1 Antagonist SR 141716A in Rhesus Monkeys Pretreated with Delta9-tetrahydrocannabinol

Overview

Journal Psychopharmacology (Berl)

Specialty Pharmacology

Date 2006 Sep 6

PMID 16953389

Citations 20

Authors

Lance R McMahon

Affiliations

Soon will be listed here.

Abstract

Rationale: Drug discrimination can be used to examine tolerance and dependence in agonist-treated animals by establishing an appropriate antagonist as a discriminative stimulus.

Objective: Establish intravenous SR 141716A as a discriminative stimulus in four rhesus monkeys pretreated with a relatively small dose of Delta9-tetrahydrocannabinol (Delta9-THC).

Methods: Rhesus monkeys received i.v. Delta9-THC (0.32 mg/kg) and discriminated i.v. SR 141716A (1 mg/kg) from vehicle while responding under a fixed ratio (FR) 5 schedule of stimulus-shock termination.

Results: The discriminative stimulus effects of SR 141716A were dose-dependent (ED50=0.33 mg/kg) and were mimicked by the CB1 antagonist AM 251 (ED50=0.98 mg/kg), but not by a benzodiazepine (midazolam) or an N-methyl-D-aspartate antagonist (ketamine). An additional dose (0.32 mg/kg in addition to 0.32 mg/kg administered before the session) of Delta9-THC shifted the SR 141716A dose-effect curve 3-fold rightward. Omitting Delta9-THC before test sessions resulted in responding on the SR 141716A lever that was attenuated by subsequent administration of Delta9-THC (ED50=0.13 mg/kg), CP 55940 (ED50=0.013 mg/kg), and WIN 55212-2 (ED50=0.35 mg/kg); midazolam and ketamine did not attenuate responding on the SR 141716A lever. SR 141716A (1 mg/kg) shifted the Delta9-THC and CP 55940 dose-effect curves 3.4-fold rightward; the WIN 55212-2 dose-effect curve was not significantly modified by a dose of 1 mg/kg of SR 141716A.

Conclusions: SR 141716A can be established as a discriminative stimulus in animals pretreated with Delta9-THC, and this assay is selective for cannabinoid activity. Differential antagonism of cannabinoids by SR 141716A might indicate that the mechanism of action of WIN 55212-2 is not identical to other cannabinoids. This study demonstrates that, under the appropriate conditions, drug discrimination has utility for examining cannabinoid dependence and withdrawal.

Citing Articles

Apparent Affinity Estimates and Reversal of the Effects of Synthetic Cannabinoids AM-2201, CP-47,497, JWH-122, and JWH-250 by Rimonabant in Rhesus Monkeys.

Hruba L, McMahon L J Pharmacol Exp Ther. 2017; 362(2):278-286.

PMID: 28533288 PMC: 5502382. DOI: 10.1124/jpet.117.240572.

Enhanced discriminative stimulus effects of Δ(9)-THC in the presence of cannabidiol and 8-OH-DPAT in rhesus monkeys.

McMahon L Drug Alcohol Depend. 2016; 165:87-93.

PMID: 27289270 PMC: 4947395. DOI: 10.1016/j.drugalcdep.2016.05.016.

Discriminative Stimulus Properties of Phytocannabinoids, Endocannabinoids, and Synthetic Cannabinoids.

Wiley J, Owens R, Lichtman A Curr Top Behav Neurosci. 2016; 39:153-173.

PMID: 27278640 DOI: 10.1007/7854_2016_24.

Human Drug Discrimination: Elucidating the Neuropharmacology of Commonly Abused Illicit Drugs.

Bolin B, Alcorn J, Reynolds A, Lile J, Stoops W, Rush C Curr Top Behav Neurosci. 2016; 39:261-295.

PMID: 27272070 PMC: 5461212. DOI: 10.1007/7854_2016_10.

Cannabinoid abuse and addiction: Clinical and preclinical findings.

Panlilio L, Goldberg S, Justinova Z Clin Pharmacol Ther. 2015; 97(6):616-27.

PMID: 25788435 PMC: 4446186. DOI: 10.1002/cpt.118.

References

Perio A, Maruani J, Barth F, Le Fur G, Soubrie P . Central mediation of the cannabinoid cue: activity of a selective CB1 antagonist, SR 141716A. Behav Pharmacol. 1996; 7(1):65-71. View

Mansbach R, Rovetti C, Winston E, Lowe 3rd J . Effects of the cannabinoid CB1 receptor antagonist SR141716A on the behavior of pigeons and rats. Psychopharmacology (Berl). 1996; 124(4):315-22. DOI: 10.1007/BF02247436. View

McMahon L, France C . Acute and chronic effects of the neuroactive steroid pregnanolone on schedule-controlled responding in rhesus monkeys. Behav Pharmacol. 2002; 13(7):545-55. DOI: 10.1097/00008877-200211000-00004. View

Jarbe T, Harris M, Li C, Liu Q, Makriyannis A . Discriminative stimulus effects in rats of SR-141716 (rimonabant), a cannabinoid CB1 receptor antagonist. Psychopharmacology (Berl). 2004; 177(1-2):35-45. DOI: 10.1007/s00213-004-1916-5. View

Bass C, Griffin G, Grier M, Mahadevan A, Razdan R, Martin B . SR-141716A-induced stimulation of locomotor activity. A structure-activity relationship study. Pharmacol Biochem Behav. 2002; 74(1):31-40. DOI: 10.1016/s0091-3057(02)00945-0. View

Wiley J, Lowe J, Balster R, Martin B . Antagonism of the discriminative stimulus effects of delta 9-tetrahydrocannabinol in rats and rhesus monkeys. J Pharmacol Exp Ther. 1995; 275(1):1-6. View

ACETO M, Scates S, Lowe J, Martin B . Dependence on delta 9-tetrahydrocannabinol: studies on precipitated and abrupt withdrawal. J Pharmacol Exp Ther. 1996; 278(3):1290-5. View

GOLD L, Balster R, Barrett R, Britt D, Martin B . A comparison of the discriminative stimulus properties of delta 9-tetrahydrocannabinol and CP 55,940 in rats and rhesus monkeys. J Pharmacol Exp Ther. 1992; 262(2):479-86. View

Beardsley P, Balster R, Harris L . Dependence on tetrahydrocannabinol in rhesus monkeys. J Pharmacol Exp Ther. 1986; 239(2):311-9. View

10.

Jarbe T, Lamb R, Lin S, Makriyannis A . (R)-methanandamide and Delta 9-THC as discriminative stimuli in rats: tests with the cannabinoid antagonist SR-141716 and the endogenous ligand anandamide. Psychopharmacology (Berl). 2001; 156(4):369-80. DOI: 10.1007/s002130100730. View

11.

Wiley J, Huffman J, Balster R, Martin B . Pharmacological specificity of the discriminative stimulus effects of delta 9-tetrahydrocannabinol in rhesus monkeys. Drug Alcohol Depend. 1995; 40(1):81-6. DOI: 10.1016/0376-8716(95)01193-5. View

12.

Mathis D, Moon R, Lal H . Animal models of drug withdrawal symptoms. Psychopharmacology (Berl). 1990; 101(3):292-309. DOI: 10.1007/BF02244046. View

13.

McMahon L, Amin M, France C . SR 141716A differentially attenuates the behavioral effects of delta9-THC in rhesus monkeys. Behav Pharmacol. 2005; 16(5-6):363-72. DOI: 10.1097/00008877-200509000-00008. View

14.

Lichtman A, Sheikh S, Loh H, Martin B . Opioid and cannabinoid modulation of precipitated withdrawal in delta(9)-tetrahydrocannabinol and morphine-dependent mice. J Pharmacol Exp Ther. 2001; 298(3):1007-14. View

15.

Smurthwaite S, Kautz M, Geter B, Riley A . Naloxone as a stimulus in drug discrimination learning: generalization to other opiate antagonists. Pharmacol Biochem Behav. 1992; 41(1):43-7. DOI: 10.1016/0091-3057(92)90056-l. View

16.

Perlin E, Smith C, Nichols A, Almirez R, Flora K, Cradock J . Disposition and bioavailability of various formulations of tetrahydrocannabinol in the rhesus monkey. J Pharm Sci. 1985; 74(2):171-4. DOI: 10.1002/jps.2600740213. View

17.

Tanda G, Munzar P, Goldberg S . Self-administration behavior is maintained by the psychoactive ingredient of marijuana in squirrel monkeys. Nat Neurosci. 2000; 3(11):1073-4. DOI: 10.1038/80577. View

18.

McMahon L, Gerak L, France C . Potency of positive gamma-aminobutyric acid(A) modulators to substitute for a midazolam discriminative stimulus in untreated monkeys does not predict potency to attenuate a flumazenil discriminative stimulus in diazepam-treated monkeys. J Pharmacol Exp Ther. 2001; 298(3):1227-35. View

19.

Compton D, ACETO M, Lowe J, Martin B . In vivo characterization of a specific cannabinoid receptor antagonist (SR141716A): inhibition of delta 9-tetrahydrocannabinol-induced responses and apparent agonist activity. J Pharmacol Exp Ther. 1996; 277(2):586-94. View

20.

Sannerud C, Young A . Environmental modification of tolerance to morphine discriminative stimulus properties in rats. Psychopharmacology (Berl). 1987; 93(1):59-68. DOI: 10.1007/BF02439587. View